← Back to Screener
GRI Bio, Inc. Common Stock (GRI)
Price$2.00
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-104.35%
Price vs S&P 500 (4W)-10.90%
VGM Score27.94
Market Capitalization$3.54M
All Metrics
Book Value / Share (Quarterly)$6.65
P/TBV (Annual)1.04x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-7.66
Price vs S&P 500 (YTD)-79.21%
EPS (TTM)$-87.47
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-87.47
EPS (Annual)$-45.61
ROI (Annual)-203.62%
Cash / Share (Quarterly)$6.97
ROA (Last FY)-143.06%
EBITD / Share (TTM)$-27.07
ROE (5Y Avg)-1160.96%
Cash Flow / Share (Annual)$-20.47
P/B Ratio0.34x
P/B Ratio (Quarterly)0.31x
Net Income / Employee (Annual)$-2,052,500
Net Interest Coverage (TTM)-5.86x
ROA (TTM)-143.23%
EPS Incl Extra (Annual)$-45.61
Current Ratio (Annual)3.25x
Quick Ratio (Quarterly)13.91x
3-Month Avg Trading Volume0.26M
52-Week Price Return-95.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.75
P/S Ratio (Annual)35.42x
Asset Turnover (Annual)0.10x
52-Week High$80.36
EPS Excl Extra (Annual)$-45.61
CapEx CAGR (5Y)8.45%
26-Week Price Return-96.43%
Quick Ratio (Annual)3.11x
13-Week Price Return-16.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.21x
Enterprise Value$-7.51M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4822.00%
Cash / Share (Annual)$16.53
3-Month Return Std Dev66.62%
Net Income / Employee (TTM)$-2,727,000
ROE (Last FY)-203.62%
Net Interest Coverage (Annual)-4.10x
EPS Basic Excl Extra (Annual)$-45.61
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-87.47
ROI (TTM)-199.52%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.21
Price vs S&P 500 (52W)-119.37%
Year-to-Date Return-71.06%
5-Day Price Return-3.38%
EPS Normalized (Annual)$-45.61
ROA (5Y Avg)-273.96%
Net Profit Margin (Annual)-4822.00%
Month-to-Date Return-2.91%
Cash Flow / Share (TTM)$-5.59
EBITD / Share (Annual)$-45.76
Operating Margin (Annual)-4788.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-1158.00%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-87.47
P/TBV (Quarterly)1.09x
P/B Ratio (Annual)0.24x
Book Value / Share (Annual)$12.07
Price vs S&P 500 (13W)-24.92%
Beta-1.23x
Revenue / Share (TTM)$0.00
ROE (TTM)-199.52%
52-Week Low$1.97
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-1.61est. -0.91
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GRIGRI Bio, Inc. Common Stock | — | — | D | $2.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
GRI Bio is a clinical-stage biotech company developing immunomodulatory therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead program, GRI-0621, is a RAR-beta/gamma dual agonist that modulates immune T cell responses, with an oral tazarotene formulation also in development. The company's pipeline includes GRI-0803, a Type 2 NKT cell agonist designed to treat autoimmune conditions.